CBI Scene Blog

5 Best Practices to Secure Enterprise-Wide Buy-In for Master Data Management

Posted by Stephanie V on Oct 9, 2014 9:43:05 AM

 

The benefits of master data management in the life sciences industry cannot be understated; the enterprise-wide MDM approach allows for better communication across departments, ultimately leading to a reduction in overhead cost and significant improvements in overall business functioning. Unfortunately, in spite of the ample evidence suggesting that MDM is the way of the future in the world of life sciences, stakeholders may not be in favor of this approach. Convincing reluctant stakeholders is possible, but it requires thorough research and a compelling presentation littered with case studies and industry-wide analytics. The securing of an enterprise-wide buy-in may be a guaranteed challenge, but the following five best practices should make reluctant stakeholders more amenable to the idea of MDM.

Read More

Topics: Compliance & Regulatory, Commercial & Patient Programs

INFOGRAPHIC: Seizing a Rare Opportunity- A Current Snapshot of the Rare Disease Community

Posted by Logan Fleck on Sep 25, 2014 9:00:00 AM

People living with rare diseases face unique obstacles that stand in the way of their treatment. Because a rare disease affects less than 200,000 Americans, these diseases can go largely unrecognized – even amongst health care providers. Technological developments and the expansion of online communities are helping to raise awareness by providing new opportunities for networking and valuable resources for patients and professionals alike.

Tracking down participants for clinical trials can be difficult and trials often occur far from patients’ homes, but drug developers are beginning to use online sharing and social media to spread the word to target communities. Individuals within these communities are also spreading the word and helping to increase involvement in trials where new treatments are in high demand. Because only about 400 approved treatments exist for rare diseases, there is pressure for new medicines to be produced quickly and most development timelines are condensed. The drugs that meet FDA criteria are released and provide great relief to a small market. However, the shortened timeline can increase the opportunity for error to occur outside of the trial and limits the amount of time for observations to ensure a drug’s maximum efficacy.

Read More

Topics: Commercial & Patient Programs, Patient Access, Patient Assistance, Rare Disease & Orphan Drugs

The Major Barriers of Entry for Therapeutic Discoveries for Rare Disease Conditions

Posted by Natalie R on Sep 24, 2014 11:36:03 AM

Contrary to what its name implies, rare diseases are anything but rare. According to NCATS, 25-30 million people in the United States suffer from rare diseases, which averages out to about 1 in 10 Americans. Worldwide, an estimated 350 million people are living with rare diseases. The terminological disconnect can be explained by the approximately 7,000 different types of rare diseases and orphan disorder—a staggering figure that is growing every day. 

Clearly, there's a high demand for cultivating research and treatments for rare diseases. So what's standing in the way?

Read More

Topics: Commercial & Patient Programs, Patient Access, Patient Assistance, speed to therapy, Rare Disease & Orphan Drugs

5 Initiatives to Advance Research into Rare Disease Therapies

Posted by Linda K on Aug 28, 2014 11:45:00 AM

Rare diseases have traditionally received far less attention from legislators, researchers and pharmaceutical companies than more prevalent health issues. Rare diseases have often been overlooked because of a myraid of reasons including: lack of research on the disease state, difficulty in finding and retaining patients to participate in clinical trials, getting coverage approvals from payers, spreading market awareness about the disroder, and the financial return of such therapies.

Read More

Topics: Commercial & Patient Programs, Patient Access, Patient Assistance, Clinical, Rare Disease & Orphan Drugs

Tips on mHealth & Healthy Habits

Posted by Mark Cullen on May 23, 2014 2:24:00 PM

Sad but true, there are thousands of great health apps that are never fully utilized. Seemingly great technologies too often fail due to lack of engagement. Research shows that many apps see a rapid drop off in users within the first three months after downloaded. So, how do we encourage patients to incorporate mobile technology into their daily lives so it becomes a routine habit, rather than a spur-of-the-moment download that falls by the wayside?

Read More

Topics: Commercial & Patient Programs

Strategic Patient Adherence Awards - Excellence in Patient Adherence

Posted by Rob Nauman on Feb 18, 2014 1:45:00 PM

Read More

Topics: Commercial & Patient Programs, Medical Affairs & Communication

INFOGRAPHIC: Innovations in Oncology Therapy & Research

Posted by Lucy Weiland on Dec 9, 2013 11:19:00 AM

By the end of 2013, nearly 1.7 million Americans will have been diagnosed with cancer. Global cancer mortality rates may grow from 12.8 million in 2008 to 22.2 million in 2030…  but our future is looking brighter thanks to oncology innovation. More Americans are surviving cancer: the prediction for 2012 cancer survivors was 12 million, but we exceeded that by almost 2 million additional survivors. With these advancements, we’re fighting back. We’re making incredible strides in cancer treatment. Oncology is a growing field with many notable successes, and it shows promise in increasing cancer survival rates and finding a real cure.

Read More

Topics: Infographics, oncolytics, Commercial & Patient Programs, Patient Access, Patient Assistance

Harry Potter’s Severus Snape & Big Pharma, a Comparison

Posted by Daria Binder on Sep 18, 2013 11:25:00 AM

Read More

Topics: Pharma Accounting & Reporting, Compliance & Regulatory, Brand & Digital Strategy, Pharma Marketing, Commercial & Patient Programs, Accounting and Contract Operations, Medical Affairs & Communication, pharma responsibility, Patient Access, Patient Assistance, Distribution and Channel

Speed to Therapy: A 5K Dash to Therapy Initiation

Posted by Brittany Lake on May 20, 2013 2:37:00 PM

Read More

Topics: Commercial & Patient Programs, patient adherence, Patient Access, speed to therapy

Why is Social Media So Important for Patient Online Reporting?

Posted by Lisa McCoun on Apr 29, 2013 4:14:00 PM

Read More

Topics: Brand & Digital Strategy, Commercial & Patient Programs